Vertex Pharma
Vertex Pharma makes progress in quest for non-opioid pain drug
Phil Taylor
Analgesic, NaV1.8, opioid, pain, Vertex Pharma
0 Comment
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Phil Taylor
Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma
0 Comment
Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance
Phil Taylor
CRISPR Therapeutics, CRISPR/Cas9, gene editing, Obsidian Therapeutics, partnering, Vertex Pharma
0 Comment
FDA fast tracks type 1 diabetes cell therapy from Vertex
Phil Taylor
cell therapy, fda, FDA fast track, Regenerative medicine, type 1 diabetes, Vertex Pharma
0 Comment
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders
Phil Taylor
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex Pharma
0 Comment
Vertex gets EU okay to treat younger cystic fibrosis patients
Phil Taylor
cystic fibrosis, ema, Kalydeco, regulatory approval, Symkevi, Vertex Pharma
0 Comment
Market Access/ Views & Analysis/ Views and analysis
Vertex Pharma’s vision for reimbursement innovation
Paul Tunnah
COVID-19, cystic fibrosis, EU Leaders, NICE, reimbursement, UK Leaders, Vertex Pharma
0 Comment
Moderna broadens R&D scope with Vertex, Chiesi alliances
Phil Taylor
Chiesi, cystic fibrosis, Moderna, partnership, pulmonary arterial hypertension, Vertex Pharma
0 Comment